ライフサイエンスコーパス: curative treatment

1 plications and growth, other admissions, and curative treatment.

2 the ability to translate this method into a curative treatment.

3 other clinicopathologic factors and type of curative treatment.

4 does not appear to be a contraindication to curative treatment.

5 en the patient eligibility for what may be a curative treatment.

6 ovides more persons with the opportunity for curative treatment.

7 cular therapy should shorten the duration of curative treatment.

8 surgery remains the mainstay of potentially curative treatment.

9 or such patients may decrease the chances of curative treatment.

10 er number of patients will benefit from this curative treatment.

11 ed patients who stand to benefit most from a curative treatment.

12 mber of days from diagnosis to initiation of curative treatment.

13 hypopharynx, or larynx undergoing first-line curative treatment.

14 ognoses, limited therapeutic options, and no curative treatment.

15 ed patients with a non-ICU policy or with no curative treatment.

16 crine disorder for which surgery is the only curative treatment.

17 ents with localized PC, candidates for local curative treatment.

18 Overall, 23% of cases received potentially curative treatment.

19 er (CRC) is common, with surgery as the main curative treatment.

20 more and novel opportunities for potentially curative treatment.

21 ong working age adults and does not have any curative treatments.

22 and with metastatic cancer not receiving any curative treatments.

23 for the development of preventative and even curative treatments.

24 ing the past 20 y, but we are still far from curative treatments.

25 Improved testing and linkage could increase curative treatment access.

26 m earlier diagnosis and access to first-line curative treatments, among which RFA provided the best v

27 Discussing no further curative treatment and hospice was reported as most diff

28 Its recognition is critical because curative treatment and prognosis require early diagnosis

29 to a higher probability of benefiting from a curative treatment and so a higher survival probability.

30 life expectancy in patients who had received curative treatment and whose hypercortisolism remained i

31 with only one third of patients eligible for curative treatments and very limited survival benefits w

32 n received primary endocrine therapy, 26 432 curative treatment, and 19 526 surveillance.

33 patients with PC received primary ET, 26,432 curative treatment, and 19,527 surveillance.

34 esection is regarded as the only potentially curative treatment, and adjuvant chemotherapy with gemci

35 ow-risk cancers are referred for unnecessary curative treatment, and much treatment is given at low-v

36 nclude immediate curative treatment, delayed curative treatment, and no treatment, with additional co

37 95% CI, 1.11 to 1.30] for men undergoing ET, curative treatment, and surveillance, respectively).

38 nefits, defined as early tumor detection and curative treatment, and surveillance-related physical ha

39 transplantation (SCT) is well accepted as a curative treatment approach for younger patients with my

40 may revert abnormal LSC function and support curative treatment approaches in this malignancy.

41 mplications are difficult to diagnose and no curative treatments are available.

42 children, yet no human vaccine nor efficient curative treatments are available.

43 ressive and debilitating condition for which curative treatments are currently unavailable.

44 a radical treatment for prostate cancer, but curative treatments are elusive for poorly differentiate

45 of patients diagnosed at early stages, when curative treatments are feasible.

46 The only curative treatments are surgical resection or liver tran

47 rogeneity is critical for the development of curative treatments as the failure to eliminate therapy-

48 l lymphotropic virus type-I (HTLV-I) without curative treatment at present.

49 lantation (alloHSCT) is the only potentially curative treatment available for patients with B-cell ch

50 DS patients are not eligible for potentially curative treatment because of advanced age and/or clinic

51 fatal, Pancoast tumours are now amenable to curative treatment because of improvements in combined m

52 Tumor resection remains the only curative treatment but is often not possible because of

53 patients who have cancer, who have completed curative treatment, but who remain at high risk for recu

54 ly recommended and an extended indication of curative treatment by HSCT should be considered.

55 unction at HCC diagnosis and better OS after curative treatment compared to counterparts with HCV and

56 is a pressing public health problem with no curative treatment currently available.

57 adiation treatment options include immediate curative treatment, delayed curative treatment, and no t

58 patients within Milan criteria submitted to curative treatments did not show any difference in survi

59 hese patients undergo palliative rather than curative treatment due to dissemination of cancer along

60 nd pharmacodynamic models more predictive of curative treatment durations are set forth.

61 ilar patterns were seen for men who received curative treatment (DVT: 1.73, 1.47-2.01; pulmonary embo

62 No curative treatment except for radical surgery (almost ne

63 ctory to available therapies or for which no curative treatments existed.

64 mmon heritable hematological disease, yet no curative treatment exists for this disorder.

65 ansplantation (HCT) represents a potentially curative treatment for a variety of hematologic malignan

66 pecimens from 116 patients who had undergone curative treatment for adenocarcinoma of the colon.

67 Since there is no curative treatment for advanced prostate cancer, explora

68 Allergen immunotherapy (AIT) is the only curative treatment for allergy.

69 end the capability of delivering potentially curative treatment for bilateral hepatic colorectal meta

70 arrow transplantation (BMT) is a potentially curative treatment for both inherited and acquired disea

71 otodynamic therapy is an effective and often curative treatment for certain solid tumors.

72 n increasingly used therapeutic strategy for curative treatment for colorectal metastases.

73 There is still no curative treatment for Duchenne muscular dystrophy (DMD)

74 Liver transplantation (LT) is the best curative treatment for early hepatocellular carcinoma (H

75 powered trials demonstrating the benefit of curative treatment for early-stage prostate cancer.

76 t the efficacy of gene transfer therapy as a curative treatment for Gaucher disease.

77 Patients who underwent curative treatment for HCC and recovered within 6 wk wer

78 transplantation (allo-HCT) is a potentially curative treatment for hematologic and immunologic disea

79 opoietic cell transplantation (HCT) can be a curative treatment for hematologic malignancies and over

80 cquired liver diseases and could represent a curative treatment for hemophilia A.

81 Despite the availability of curative treatment for hepatitis C virus (HCV) infection

82 y patients who, after undergoing potentially curative treatment for hepatocellular carcinoma, are at

83 Allogeneic bone marrow transplantation is a curative treatment for leukemia and lymphoma, but graft-

84 Esophagectomy is an important, potentially curative treatment for localized esophageal cancer, but

85 atopoietic cell transplantation (HCT) can be curative treatment for lymphoid malignancies, but it has

86 Bone marrow transplantation is a curative treatment for many diseases, including leukemia

87 oietic stem cell transplantation is the only curative treatment for many malignant hematologic diseas

88 ection represents the best and a potentially curative treatment for metastatic colorectal cancer to t

89 c stem cell transplantation remains the only curative treatment for myelodysplastic syndrome.

90 on of autoimmune conditions, but there is no curative treatment for neurodegenerative conditions.

91 Surgical resection is the only curative treatment for pancreatic and periampullary canc

92 Curative treatment for patients with advanced head and n

93 cell transplantation (HSCT) remains the only curative treatment for patients with Fanconi anemia (FA)

94 Mr A needs surgery for potentially curative treatment for presumed colon cancer, but he is

95 Treatment selection for men undergoing curative treatment for prostate cancer is often a challe

96 anscription, suggesting that even apparently curative treatment for PTB may not eradicate all of the

97 Liver transplantation (LT) represents a curative treatment for small hepatocellular carcinoma (H

98 There is currently no curative treatment for this disorder.

99 Allergen-specific immunotherapy is the only curative treatment for type I allergy.

100 stem cell (HSC) transplantation represents a curative treatment for various hematological disorders.

101 Surgery is the most effective curative treatment for various tumour types.

102 cancer is now favorable, there are still no curative treatments for castration-resistant prostate ca

103 Surgery and radiation continue to be curative treatments for localized disease but have adver

104 Resistance to therapy and lack of curative treatments for metastatic breast cancer suggest

105 liver transplantation (CLT) are potentially curative treatments for patients with hepatocellular car

106 olid tumors and thus a therapeutic target in curative treatments for solid cancers.

107 successful remission; however, there are no curative treatments for tumors that have progressed beyo

108 Patients were stratified by curative treatment, geography, Child-Pugh status, and re

109 he subset that received guideline-concordant curative treatment (hazard ratio, 2.63; 95% CI, 1.05 to

110 p < 0.001), and a decreased eligibility for curative treatment (HBV-14%, HCV-34%; p < 0.05).

111 c T cell response may also be required after curative treatment if residual latently infected cells r

112 ulfilled Milan criteria in 79.3%, leading to curative treatment in 70.4%.

113 o might benefit from novel therapies or even curative treatment in the form of hematopoietic cell tra

114 The group most likely to receive curative treatment in the SEER-Medicare cases was patien

115 transplantation remains the only potentially curative treatment in this disorder, but many recent stu

116 Socioeconomic factors affect selection of curative treatments in HL.

117 sed with early disease over time, the use of curative treatments in this patient group has recently p

118 ng breast cancer care from diagnosis through curative treatment into survivorship, and metastatic dis

119 ly leads to end-stage kidney disease, and no curative treatment is available.

120 Curative treatment is limited to allogeneic hematopoieti

121 cause most patients are diagnosed late, when curative treatment is not possible.

122 The only potentially curative treatment is the surgical resection of the prim

123 Curative treatment is then initiated at the first sign o

124 anges over time for those who survived since curative treatment is unknown.

125 neurodegenerative disease, currently without curative treatment, is associated with the accumulation

126 reatment course including current first-line curative treatment: liver resection, radiofrequency abla

127 nd transplantation has become one of the few curative treatment modalities for patients with HCC, esp

128 In spite of great advances in the design of curative treatments, most patients currently receive pal

129 e first patient received RF ablation for the curative treatment of a solitary residual hepatic mass f

130 Despite advances in the curative treatment of acute myeloid leukemia (AML), recu

131 Curative treatment of aggressive Kaposi sarcoma (KS) wit

132 hematopoietic stem cell transplantation as a curative treatment of chronic myeloid leukemia (CML).

133 cessible with endoscopy, early diagnosis and curative treatment of esophageal cancer is possible.

134 cell transplantation (HSCT) remains the only curative treatment of FA patients with MDS or AML.

135 From 2000 to 2010, 303 patients underwent curative treatment of HCC; 52 (17.2%) and 162 (53.5%) pa

136 The prevention of tumor recurrence after curative treatment of hepatocellular carcinoma (HCC) is

137 ic resonance (MR) imaging on eligibility for curative treatment of hepatocellular carcinoma (HCC).

138 transplantation is effective and potentially curative treatment of hereditary fibrinogen amyloidosis.

139 Tumor resistance to current drugs prevents curative treatment of human colon cancer.

140 Curative treatment of intrahepatic cholangiocarcinoma (I

141 The curative treatment of locally advanced head and neck squ

142 een successfully integrated into potentially curative treatment of locally advanced squamous-cell car

143 y (CRT) is an alternative to surgery for the curative treatment of oesophageal carcinoma.

144 While R0 resection remains the mainstay of curative treatment of patients with GEJ cancer, the opti

145 After curative treatment of patients with HCC, one 2,200-MBq d

146 ne and tafenoquine) are used for the radical curative treatment of Plasmodium vivax malaria and can c

147 stem cell transplantation (HSCT) is the only curative treatment of severe congenital neutropenia (SCN

148 rove to be the final frontier in the optimal curative treatment of these disorders.

149 nsplantation is hampered in its success as a curative treatment of type 1 diabetes by the absence of

150 far proved effective both for preventive and curative treatments of AMR in sensitized patients and pa

151 -marrow transplantation (BMT) has provided a curative treatment option for chronic myeloid leukaemia

152 Currently, salvage RP represents the only curative treatment option for these patients.

153 Radiotherapy is a curative treatment option in prostate cancer.

154 or combination therapy has failed to offer a curative treatment option, most likely because these pat

155 ent brentuximab vedotin may be a potentially curative treatment option.

156 itor crizotinib in patients who had no known curative treatment options at diagnosis or with relapsed

157 umors to become surgical candidates, provide curative treatment options in nonsurgical candidates, or

158 Because of the lack of curative treatment options, interferons (IFN) have been

159 on and liver transplantation remain the only curative treatment options.

160 n indolent cancer, with effective but rarely curative treatment options.

161 sk in 76,600 patients with PC undergoing ET, curative treatment, or surveillance.

162 ncer who were receiving endocrine treatment, curative treatment, or surveillance.

163 After radical curative treatment, participants were randomly assigned

164 ffective than benznidazole and nifurtimox as curative treatments, particularly for acute stage infect

165 (odds ratio [OR] 2.08, 95% CI 1.80-2.37) and curative treatment rates (OR 2.24, 95% CI 1.99-2.52).

166 ported rates of early stage tumor detection, curative treatment receipt, or survival, stratified by H

167 he availability of effective diagnostics and curative treatment regimens for tuberculosis, millions o

168 III clinical trial design has lagged in the curative treatment setting, particularly in combination

169 of alternative, synergistic, and potentially curative treatment strategies.

170 antiretroviral therapy following potentially curative treatment strategies.

171 n oesophageal cancer that was unsuitable for curative treatment, symptomatic dysphagia, Eastern Coope

172 In the absence of curative treatment, the management of pre-eclampsia invo

173 After a median follow-up of 50 months after curative treatment, the most frequent cause of death was

174 However, given the lack of a curative treatment, the prognosis of NMO remains poor in

175 s, it is becoming possible to offer targeted curative treatments to more and more patients.

176 umor size, count, and receipt of potentially curative treatments (transplantation, resection, and abl

177 Currently, curative treatment trials for Alzheimer's disease (AD) h

178 Of over 19 patients identified with E-GISTs, curative treatment was surgical for 16 patients, with en

179 ase but not to be candidates for potentially curative treatment were compared (1992-2002).

180 y to therapy and for whom there was no known curative treatment were eligible.

181 ollow-up of less than 5 years since the last curative treatment were excluded from the analysis.

182 ave advanced disease that is not amenable to curative treatment, which means that they are likely to

183 ell transplantation (HSCT) was found to be a curative treatment with a relatively good prognosis beca

184 In addition, we tested the efficacies of curative treatments with either the MIF antagonist ISO-1

185 and gene therapy continue to be evaluated as curative treatments with increasing success rates for so

186 Finally, we found that curative treatments with the MIF antagonist ISO-1 or ant

187 l resection is currently considered the only curative treatment, with only about 25% of patients bein

188 lower dose than required to achieve the same curative treatment without MDNPs.